Vera Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vera Therapeutics, Inc. on November 25, 2025. The filing reports the appointment of a new director to the Board of Directors and associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and director compensation.
Material Changes
On November 25, 2025, the Board appointed James R. Meyers as a Class II Director, effective immediately. Mr. Meyers was also appointed to the Audit Committee. This appointment triggers specific compensatory awards under the Company's Non-Employee Director Compensation Policy.
Compensatory Arrangements and Outlook
- Initial Option Grant: Mr. Meyers received a nonstatutory stock option to purchase 25,000 shares of Class A common stock. These options vest monthly over a three-year period, contingent on continuous service.
- Cash Retainer: Mr. Meyers will receive an annual cash retainer of $40,000 for Board service and $10,000 for Audit Committee service. These amounts are pro-rated for the remainder of 2025.
- Future Grants: Commencing with the 2026 Annual Meeting, Mr. Meyers is eligible for annual option grants for the lesser of 14,000 shares or a grant date fair value of $400,000. These future grants vest on the earlier of the first anniversary of the grant date or the next annual meeting.
- Indemnification: Mr. Meyers will enter into the Company's standard indemnification agreement.
The filing states there are no related person transactions or undisclosed arrangements regarding Mr. Meyers' selection.
Investor Verification Checklist
- Verify the current share price to assess the potential dilution impact of the 25,000 initial option shares.
- Review the Company's Amended and Restated Non-Employee Director Compensation Policy for full terms of vesting and exercise.
- Confirm the pro-rated cash compensation calculation for the partial year of 2025.
- Monitor future filings for the 2026 Annual Meeting to confirm the execution of subsequent annual option grants.